176 related articles for article (PubMed ID: 22075505)
1. The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease.
Moon HW; Noh J; Yun YM; Kim HY; Yun IJ; Song J; Kim JQ
Ann Clin Lab Sci; 2011; 41(3):229-35. PubMed ID: 22075505
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
[TBL] [Abstract][Full Text] [Related]
3. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.
Kwon A; Jo SH; Im HJ; Jo YA; Park JY; Kang HJ; Kim HS; Cho HC; Lee YK
J Thromb Thrombolysis; 2011 Nov; 32(4):467-73. PubMed ID: 21713378
[TBL] [Abstract][Full Text] [Related]
5. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
6. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
[TBL] [Abstract][Full Text] [Related]
7. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
[TBL] [Abstract][Full Text] [Related]
9. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
[TBL] [Abstract][Full Text] [Related]
10. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
[TBL] [Abstract][Full Text] [Related]
13. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin.
Sangviroon A; Panomvana D; Tassaneeyakul W; Namchaisiri J
Drug Metab Pharmacokinet; 2010; 25(6):531-8. PubMed ID: 20930419
[TBL] [Abstract][Full Text] [Related]
16. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.
Lu Y; Yang J; Zhang H; Yang J
Clin Pharmacokinet; 2013 Jul; 52(7):567-81. PubMed ID: 23515956
[TBL] [Abstract][Full Text] [Related]
17. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.
Zhu Y; Shennan M; Reynolds KK; Johnson NA; Herrnberger MR; Valdes R; Linder MW
Clin Chem; 2007 Jul; 53(7):1199-205. PubMed ID: 17510308
[TBL] [Abstract][Full Text] [Related]
18. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.
Lacut K; Ayme-Dietrich E; Gourhant L; Poulhazan E; Andro M; Becquemont L; Mottier D; Le Gal G; Verstuyft C
Br J Clin Pharmacol; 2012 Mar; 73(3):428-36. PubMed ID: 21883387
[TBL] [Abstract][Full Text] [Related]
19. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
20. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes.
Moreau C; Pautas E; Gouin-Thibault I; Golmard JL; Mahé I; Mulot C; Loriot MA; Siguret V
J Thromb Haemost; 2011 Apr; 9(4):711-8. PubMed ID: 21255252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
